Epiomic Epidemiology Series: Onychomycosis Forecast in 22 Major Markets 2018–2028

June 2018 | 100 pages | ID: E0553EE31D6EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Onychomycosis in 22 Major Markets

Onychomycosis is a fungal infection of the nail which occurs in the hands or feet. The more notable causative agents include the fungal pathogens Trichophyton rubrum and Trichophyton mentagrophytes. This report provides the current prevalent population for Onychomycosis across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Denmark, Finland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patient groups divided by disease classification, aetiology, main symptoms and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Onychomycosis include:

• Diabetes
• Tinea pedis
• Peripheral vascular disease
• HIV / AIDS
• Psoriasis
• Hypercholesterolaemia
• Osteoarticular disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global Onychomycosis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Onychomycosis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Useful in the identification and trend of the prevalence numbers for the different causative agents of Onychomycosis.
• Provide a level of understanding on the impact from specific co-morbid conditions on Onychomycosis prevalent population.
• Identify sub-populations within Onychomycosis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Onychomycosis patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR ONYCHOMYCOSIS
FEATURES OF ONYCHOMYCOSIS PATIENTS
  CLASSIFICATION
  AETIOLOGY
  SIGNS
  COMORBIDITIES OF ONYCHOMYCOSIS PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Definition of main onychomycosis types
Table 2. Prevalence of onychomycosis, total (000s)
Table 3. Prevalence of onychomycosis, males (000s)
Table 4. Prevalence of onychomycosis, females (000s)
Table 5. Patients with clinically diagnosed onychomycosis, total (000s)
Table 6. Clinically diagnosed onychomycosis patients with current active infection, total (000s)
Table 7. New cases of clinically diagnosed onychomycosis per year, total (000s)
Table 8. Patients with clinically diagnosed onychomycosis by site of infection, total (000s)
Table 9. Patients with clinically diagnosed onychomycosis by major clinical presentation type, total (000s)
Table 10. Patients with clinically diagnosed DLSO by severity, total (000s)
Table 11. Patients with clinically diagnosed onychomycosis by duration of disease, total (000s)
Table 12. Patients with clinically diagnosed onychomycosis by causative agent, total (000s)
Table 13. Patients with clinically diagnosed dermatophyte onychomycosis by type, total (000s)
Table 14. Patients with clinically diagnosed non-dermatophyte onychomycosis by type, total (000s)
Table 15. Patients with clinically diagnosed yeast onychomycosis by type, total (000s)
Table 16. Patients with clinically diagnosed mould onychomycosis by type, total (000s)
Table 17. Clinically diagnosed onychomycosis patients with signs of infection, total (000s)
Table 18. Clinically diagnosed onychomycosis patients with skin discolouration, total (000s)
Table 19. Clinically diagnosed onychomycosis patients with hyperkeratosis, total (000s)
Table 20. Clinically diagnosed onychomycosis patients with onycholysis, total (000s)
Table 21. Clinically diagnosed onychomycosis patients with damaged nail, total (000s)
Table 22. Clinically diagnosed onychomycosis patients with paronychia, total (000s)
Table 23. Clinically diagnosed onychomycosis patients with diabetes, total (000s)
Table 24. Clinically diagnosed onychomycosis patients with tinea pedis, total (000s)
Table 25. Clinically diagnosed onychomycosis patients with tinea pedis by subtype, total (000s)
Table 26. Clinically diagnosed onychomycosis patients with tinea pedis by causative agent, total (000s)
Table 27. Tinea pedis patients with recurrent onychomycosis, total (000s)
Table 28. Abbreviations and acronyms used in the report
Table 29. USA prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 30. USA prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 31. Canada prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 32. Canada prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 33. France prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 34. France prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 35. Germany prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 36. Germany prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 37. Italy prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 38. Italy prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 39. Spain prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 40. Spain prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 41. UK prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 42. UK prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 43. Poland prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 44. Poland prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 45. Netherlands prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 46. Netherlands prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 47. Sweden prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 48. Sweden prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 49. Denmark prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 50. Denmark prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 51. Finland prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 52. Finland prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 53. Russia prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 54. Russia prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 55. Turkey prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 56. Turkey prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 57. Japan prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 58. Japan prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 59. China prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 60. China prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 61. South Korea prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 62. South Korea prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 63. India prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 64. India prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 65. Australia prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 66. Australia prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 67. Brazil prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 68. Brazil prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 69. Mexico prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 70. Mexico prevalence of onychomycosis by 5-yr age cohort, females (000s)
Table 71. Argentina prevalence of onychomycosis by 5-yr age cohort, males (000s)
Table 72. Argentina prevalence of onychomycosis by 5-yr age cohort, females (000s)